CRISPR Therapeutics AG (CRSP)

Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitab...

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

Is this finally the year CRISPR Therapeutics (CRSP 6.33%) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42% since t...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.47. This compares to a loss of $1.49 per share a year ago.

CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, indicating a -2.46% shift from the previous trading day.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...